Clinical trials: Hepatic Function Abnormal
Cancer, Liver Dysfunction
Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction
The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe…
- Trial name
- NCT03519074
- Testing
- TS-1 combined with cisplatin
- Where
- 2 sites in Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Aspergillosis Invasive
Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction
Liposomal amphotericin B is an antifungal agent commonly used to treat invasive aspergillosis, a severe fungal infection associated with high mortality in critically ill patients.
- Trial name
- NCT07337720
- Testing
- LIposomal amphotericin B (L-AmB) treatment
- Volunteers
- 40 people
- Sponsor
- Southeast University, China
Liver Failure, Liver Diseases
Biliary Anastomosis Using Surgical Loupe Versus Microscope in Living Donor Liver Transplantation
Comparison of biliary complications in right lobe living donor liver transplantation patients undergoing biliary reconstructions using microscope versus surgical loupes .
- Conditions
- Liver Failure, Liver Diseases, Liver Cancer, Liver Neoplasms
- Trial name
- NCT04618692
- Testing
- Surgical Loupes, Microscope
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Istanbul Medipol University Hospital
Sepsis, Acute Infection
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine
The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of…
- Conditions
- Sepsis, Acute Infection, Severe Infection
- Trial name
- IMPACT-NAC (NCT07273071)
- Testing
- N-Acetylcysteine (NAC) Treatment
- Where
- Denmark
- Volunteers
- 360 people
- Sponsor
- Theis S. Itenov
Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)
- Trial name
- NCT02795637
- Testing
- dasotraline
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Intubation, Intratracheal
Intubation Conditions During ERCP With Lidocaine Aerosol Plus Low-dose Cisatracurium or Conventional-dose Cisatracurium
This clinical study investigates the effects of lidocaine aerosol as an adjunct to low-dose cisatracurium for endotracheal intubation during ERCP (Endoscopic Retrograde Cholangiopancreatography) procedures.
- Trial name
- NCT07185074
- Testing
- Cisatracurium 0.05 mg/kg IV, Cisatracurium 0.15 mg/kg IV, Lidocaine aerosol 2.4% topical
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Jiangang Song
Hepatic Insufficiency
A Study of Tirzepatide in Participants With Impaired Liver Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.
- Trial name
- NCT03940742
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Liver Dysfunction
Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients
To evaluate the pharmacokinetic difference of anlotinib hydrochloride capsule between mild/moderate liver dysfunction subjects and healthy subjects, and to provide basis for formulating the clinical drug regimen for patients with…
- Trial name
- NCT05559242
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Liver Dysfunction
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes.
- Trial name
- INTERLIVER (NCT03193151)
- Testing
- liver biopsy
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 300 people
- Sponsor
- University of Alberta
Liver Dysfunction
Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
The objective of the study is to compare the pharmacokinetics profiles and safety of Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral dose of Evogliptin
- Trial name
- NCT02754219
- Testing
- Evogliptin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Congenital Heart Disease, Liver Dysfunction
Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.
Liver dysfunction is a well-documented complication in patients with congenital heart disease (CHD). The mechanisms leading to hepatic dysfunction may be multifactorial.
- Trial name
- CHD (NCT07144501)
- Testing
- Ultrasonography, Blood Sampling
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Liver Dysfunction, Healthy
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild…
- Trial name
- NCT06916078
- Testing
- Lepodisiran
- Where
- 4 sites in United States, Hungary
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency
This was an extension study to Study LAL-CL01 (NCT01307098). The primary objective of the study was to evaluate the long-term safety and tolerability of sebelipase alfa in participants with liver dysfunction due to lysosomal acid…
- Conditions
- Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
- Trial name
- NCT01488097
- Testing
- sebelipase alfa
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Dysfunction
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
This is a single center, open-label, non-randomized, 1:1 parallel control and single dose administration study design. Healthy subjects will be matched to moderate hepatic function impaired (Child-Pugh B，7-9) subjects in age…
- Trial name
- NCT02604498
- Testing
- Nemonoxacin
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhejiang Medicine Co., Ltd.
Sepsis, Liver Dysfunction
Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury
The previous research of our research group shows that during the course of sepsis, the pyroptosis mediated by the caspase-4/GSDMD pathway in immune cells, induced by pathogens, is the main cause of immune collapse in sepsis…
- Trial name
- NCT06220929
- Testing
- Mecobalamin, Ceftriaxone Sodium, Saline
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Provincial People's Hospital
Hepatorenal Syndrome, Liver Regeneration
Plasma and Hemodynamic Markers During Hepatectomy
Introduction Liver resection is considered the only curative treatment option for mCRC patients without extrahepatic disease and is accepted practice.
- Trial name
- NCT01700231
- Testing
- Liver resection
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Medical University of Vienna
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome).
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Renal Function Abnormal, Portal Hypertension
- Trial name
- LSD-RFPH (NCT07585786)
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Hepatic Function Abnormal
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
The purpose of this parallel group, Phase 1, open-label, 2-arm, single dose, multi-center study is to assess the effect of mild hepatic impairment on pharmacokinetics (PK), safety and tolerability of tolebrutinib compared with…
- Trial name
- NCT05283915
- Testing
- tolebrutinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sanofi
Neoplasm Metastases, Hepatic Insufficiency
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
- Trial name
- NCT01273493
- Testing
- Trabectedin, Dexamethasone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Hepatic Impairment, Healthy Volunteers
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
The purpose of this study is to understand the effects of liver functional impairment on the study medicine (PF-07081532). People with liver functional impairment may process the study medicine differently from healthy people.
- Trial name
- NCT05478603
- Testing
- PF-07081532
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer